icp-248
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Mar 9, 2023 (NCT05728658)
Timeline
Indications
Mechanism of action
- Apoptosis regulator Bcl-2INHIBITOR
BCL2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07082686 | Phase 2 | Aug 21, 2025 | Beijing InnoCare Pharma Tech Co., Ltd. |
| NCT06656494 | Phase 1 | Nov 30, 2024 | Beijing InnoCare Pharma Tech Co., Ltd. |
| NCT06378138 | Phase 2/Phase 3 (Phase 3) | May 15, 2024 | Beijing InnoCare Pharma Tech Co., Ltd. |
| NCT06351527 | Phase 1 | Apr 25, 2024 | Beijing InnoCare Pharma Tech Co., Ltd. |
| NCT05728658 | Phase 1 | Mar 9, 2023 | Beijing InnoCare Pharma Tech Co., Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing InnoCare Pharma Tech Co., Ltd. | For profit | 5 | 5 | 3 | 2023 |
1 organizations
Page 1 / 1